NRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19

1
1
Favorite

NRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19

T-Reuters2021-08-30

NRX Pharmaceuticals Inc :Nrx Pharmaceuticals Announces New Finding From Zyesami™ (Aviptadil) Phase 2B/3 Clinical Trial.Nrx Pharmaceuticals Inc -Zyesami Phase 2B/3 Clinical Trial Demonstrating Clinically Significant Relief From Respiratory Distress In Critical Covid-19.Nrx Pharmaceuticals Inc - Has Provided Updated Data To Us Fda In Support Of Emergency Use Authorization Request For Zyesami.Nrx Pharmaceuticals Inc -To Submit Breakthrough Therapy Designation To Fda For Zyesami For Treating Respiratory Failure In Critical Covid-19 Patients.Nrx Pharmaceuticals Inc -Patients Treated With Zyesami Showed Improvement In Blood Oxygen, Within A Day Of Starting Treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

mjvelonza
·2021-09-17
Okay but why so poorly reflected in stock price?
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2163886644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-30 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2163886644","market":"us","top_or_hot":-1,"title":"NRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19","media":"T-Reuters","content":"<html><body><p>NRX Pharmaceuticals Inc <nrxp.o>:Nrx Pharmaceuticals Announces New Finding From Zyesami™ (Aviptadil) Phase 2B/3 Clinical Trial.Nrx Pharmaceuticals Inc -Zyesami Phase 2B/3 Clinical Trial Demonstrating Clinically Significant Relief From Respiratory Distress In Critical Covid-19.Nrx Pharmaceuticals Inc - Has Provided Updated Data To Us Fda In Support Of Emergency Use Authorization Request For Zyesami.Nrx Pharmaceuticals Inc -To Submit Breakthrough Therapy Designation To Fda For Zyesami For Treating Respiratory Failure In Critical Covid-19 Patients.Nrx Pharmaceuticals Inc -Patients Treated With Zyesami Showed  Improvement In Blood Oxygen, Within A Day Of Starting Treatment.</nrxp.o></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRX Pharmaceuticals Treatment Trial Shows Significant Relief From Respiratory Distress In Critical COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>T-Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NRX Pharmaceuticals Inc :Nrx Pharmaceuticals Announces New Finding From Zyesami™ (Aviptadil) Phase 2B/3 Clinical Trial.Nrx Pharmaceuticals Inc -Zyesami Phase 2B/3 Clinical Trial Demonstrating ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2163886644","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2163886644","pubTimestamp":1630325942,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"NRX Pharmaceuticals Inc :Nrx Pharmaceuticals Announces New Finding From Zyesami™ (Aviptadil) Phase 2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","SANA":"Sana Biotechnology, Inc.","APR":"Apria, Inc.","NRXP":"NRX Pharmaceuticals Inc.","LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc."},"translate_title":"NRX药物治疗试验显示重症新冠肺炎呼吸窘迫得到显著缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APR":0.9,"CGEM":0.9,"LABP":0.9,"LHDX":0.9,"NRXP":0.9,"SANA":0.9},"content_text":"NRX Pharmaceuticals Inc :Nrx Pharmaceuticals Announces New Finding From Zyesami™ (Aviptadil) Phase 2B/3 Clinical Trial.Nrx Pharmaceuticals Inc -Zyesami Phase 2B/3 Clinical Trial Demonstrating Clinically Significant Relief From Respiratory Distress In Critical Covid-19.Nrx Pharmaceuticals Inc - Has Provided Updated Data To Us Fda In Support Of Emergency Use Authorization Request For Zyesami.Nrx Pharmaceuticals Inc -To Submit Breakthrough Therapy Designation To Fda For Zyesami For Treating Respiratory Failure In Critical Covid-19 Patients.Nrx Pharmaceuticals Inc -Patients Treated With Zyesami Showed  Improvement In Blood Oxygen, Within A Day Of Starting Treatment.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":884951645,"gmtCreate":1631849313787,"gmtModify":1676530652191,"author":{"id":"4087426878489470","authorId":"4087426878489470","name":"mjvelonza","avatar":"https://static.tigerbbs.com/c5b17614ead945ff21352a4d3bbcd990","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087426878489470","authorIdStr":"4087426878489470"},"htmlText":"Okay but why so poorly reflected in stock price?","listText":"Okay but why so poorly reflected in stock price?","text":"Okay but why so poorly reflected in stock price?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/884951645","repostId":2163886644,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}